These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18426581)

  • 1. Estimated pre-morbid IQ effects on cognitive and functional outcomes in Alzheimer disease: a longitudinal study in a treated cohort.
    Starr JM; Lonie J
    BMC Psychiatry; 2008 Apr; 8():27. PubMed ID: 18426581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
    Wattmo C; Wallin AK; Minthon L
    BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.
    Feldman H; Gauthier S; Hecker J; Vellas B; Emir B; Mastey V; Subbiah P;
    J Am Geriatr Soc; 2003 Jun; 51(6):737-44. PubMed ID: 12757558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
    Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R
    J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
    Wattmo C; Paulsson E; Minthon L; Londos E
    Clin Interv Aging; 2013; 8():329-39. PubMed ID: 23682212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
    Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
    Thomas A; Iacono D; Bonanni L; D'Andreamatteo G; Onofrj M
    Clin Neuropharmacol; 2001; 24(1):31-42. PubMed ID: 11290880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NART as an index of prior intellectual functioning: a retrospective validity study covering a 66-year interval.
    Crawford JR; Deary IJ; Starr J; Whalley LJ
    Psychol Med; 2001 Apr; 31(3):451-8. PubMed ID: 11305853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease.
    Gauthier S; Lopez OL; Waldemar G; Jones RW; Cummings J; Zhang R; Schindler R; Schwam E
    Int Psychogeriatr; 2010 Sep; 22(6):973-83. PubMed ID: 20534179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
    Gustavsson A; Jönsson L; Parmler J; Andreasen N; Wattmo C; Wallin ÅK; Minthon L
    Eur J Health Econ; 2012 Oct; 13(5):561-8. PubMed ID: 21822729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.